
Related Articles, Li





1: Curr Med Chem. 2001 Nov;8(13):1605-48.



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	ОМІМ	Вc
Search PubMed	<b>E</b> .	for Limits	Preview/Index	Histor	ý	Go Clear Clipboard	Detail	S <sup>°</sup>
About Entrez	) Bi	splay Abstra	ct C	Show: 20	Sort	Send t	0 Text	

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Peptide-binding G protein-coupled receptors: new opportunities for drug design.

Gurrath M.

Heinrich-Heine University, Pharmaceutical Chemistry, Universitatsstr. 1, 40225 Dusseldorf, Germany. gurrath@pharm.uni-duesseldorf.de

Over the last decades distinct members of the G Protein-Coupled Receptor (GPCR) family emerged as prominent drug targets within pharmaceutical research, since approximately 60 % of marketed prescription drugs act by selectively addressing representatives of that class of transmembrane signal transduction systems. It is noteworthy that the majority of GPCR-targeted drugs elicit their biological activity by selective agonism or antagonism of biogenic monoamine receptors, while the development status of peptidebinding GPCR-addressing compounds is still in its infancy. Exemplified on selected medicinal chemistry projects, this review will focus on the opportunities of therapeutic intervention into a broad spectrum of disease processes through agonizing or antagonizing the functions of peptide-binding GPCRs. In this context, a brief overview of GPCR-mediated signal transduction pathways will be given in order to emphasize the biomedical relevance of a controlled modulation of receptor function. Modern trends on lead finding and optimization strategies for peptide-binding GPCR-targeted low-molecular weight compounds will be highlighted on the basis of current research programs conducted in the areas of angiotensin II, endothelin, bradykinin, neurokinin, neuropeptide Y, LHRH, C5a antagonists, and somatostatin agonists, respectively. Special emphasis will be laid on the elaboration and utilization of structural rationales on the potential drug candidates, thus facilitating more detailed insights into the underlying molecular recognition event.

Publication Types:

- Review
- Review, Tutorial

PMID: 11562281 [PubMed - indexed for MEDLINE]

Display	Abstract	OHOW.	20	Sort 😨	Send to Te	
No JAN SAND BY CANADA CONSTRUCTION BY	- NAC AND ADDRESS AS THE PROPERTY PROPERTY AND ADDRESS AS A SECOND PROPERTY AS A SECOND		and the same of the	THE THE PARTY OF T		- transference

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Freedom of Information Act | Disclaimer

Jun 12 2003 10:1